Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Peptide safety during perimenopause Generally safe peptides: CJC-1295 + Ipamorelin (excellent safety record) BPC-157 (very safe long-term) Selank (minimal side effects) Semax (well-tolerated) GHK-Cu (safe topical and injectable) Start conservatively: Lower doses than younger women Hormones already unstable More sensitive during transition Titrate slowly Monitor carefully: Track symptoms meticulously Regular bloodwork Adjust based on response Stop if concerning effects Contraindications and cautions Avoid peptides if: Active cancer (theoretical GH concerns) Uncontrolled hypertension Severe kidney or liver disease Use caution with: Breast cancer history (discuss with oncologist) Diabetes (monitor glucose with GLP-1s) Thyroid issues (monitor thyroid function) Multiple medications (check interactions) Discuss with physician: Any chronic health conditions If on multiple medications Cancer history Cardiovascular issues See our peptide safety and risks , are peptides legal , research vs pharmaceutical peptides , and peptides vs SARMS
PlexusDx's test analyzes 14 metabolic pathways and 150+ genetic insights, including FTO and MC4R variants that influence fat oxidation and energy metabolism
10.1016/j.riam.2009.06.003 69 LeeJ
The combination of Ipamorelin and CJC-1295 is similar to that of our Sermorelin, with the GHRPs 6/2, with fewer side effects
GHRP-6 + GHRH Analogs (General) The same synergistic principle applies to any GHRH analog, including tesamorelin and sermorelin
9 : 161169 Angelucci L, Ramacci MT
